The 49 references in paper N. Vatutin T., A. Smirnova S., Н. Ватутин Т., А. Смирнова С. (2016) “Коморбидность хронической обструктивной болезни легких и сердечно6сосудистой патологии: особенности лечения // Treatment of comorbid chronic obstructive pulmonary disease and cardiovascular disease” / spz:neicon:pulmonology:y:2016:i:3:p:364-371

1
Global strategy for the diagnosis, management, and preven" tion of chronic obstructive pulmonary disease. (Global Initiative for Chronic Obstructive lung Disease (GOLD). The updated 2015 report is available on www.goldcopd.com).
(check this in PDF content)
2
Крюков Н.Н., Шанина И.Ю., Протасов А.Д. Результаты функциональных тестов у больных с ИБС в сочетании с ХОБЛ.Фундаментальные исследования. 2011; 2: 83–88.
(check this in PDF content)
3
Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8–11.
(check this in PDF content)
4
Кубажи Х. Особенности течения и прогноза у больных хронической обструктивной болезнью легких в сочета" нии с ишемической болезнью сердца и артериальной ги" пертензией: Дисс. ... канд. мед. наук. Рязань; 2013.
(check this in PDF content)
5
Вахненко А.В. Современные подходы лечения хроничес" кой обструктивной болезни легких с сопутствующей хронической сердечной недостаточностью. Світ медици# ни та біології.2013; 3: 70–73.
(check this in PDF content)
6
Гурова А.Ю., Чаплыгин А.В., Свет А.В. и др. Особеннос" ти рациональной фармакотерапии бета"адреноблокато" рами при сочетании ишемической болезни сердца и хро" нической обструктивной болезни легких. Лечащий врач. 2012; 2.
(check this in PDF content)
7
Short P.M., Lipworth S.I., Elder D.H. et al. Effect of beta blockers in treatment of chronic obstructive pulmonary dis" ease: a retrospective cohort study. Br. Med. J. 2011; 342: d2549.
(check this in PDF content)
8
Rasmussen D.B., Lange P., Jensen M.T. Patients with chron" ic obstructive pulmonary disease and heart disease can benefit from beta"blocker treatment. Ugeskr. Laeger.2015; 177 (38): V02150184.
(check this in PDF content)
9
Стаценко М.Е., Деревянченко М.В. Возможности при" менения бета"адреноблокаторов в лечении сердечно"со" судистых заболеваний у больных хронической обструк" тивной болезнью легких. Фарматека. 2013; 15: 9–15.
(check this in PDF content)
10
Bhatt S.P., Wells J.M., Kinney G.L. et al. β"Blockers are asso" ciated with a reduction in COPD exacerbations. Thorax. 2016; 71 (1): 8–14.
(check this in PDF content)
11
Andell P., Erlinge D., Smith J.G. et al. β"Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study.J. Am. Heart Ass. 2015; 4: e001611.
(check this in PDF content)
12
Kubota Y., Asai K., Furuse E. et al. Impact of β"blocker selec" tivity on long"term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 515–523.
(check this in PDF content)
13
Martiniuc C., Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev. Med. Chir. Soc. Med. Nat. Iasi.2012; 116 (1): 218–221.
(check this in PDF content)
14
Frans H. Rutten. β"Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.Arch. Intern. Med. 2010; 170 (10): 880–887.
(check this in PDF content)
15
Malerba M., Montuschi P., Radaeli A., Pirisi M. Role of beta" blockers in patients with COPD: current perspective. Drug Discov. Today. 2015; 20 (1): 129–135.
(check this in PDF content)
16
Mascitelli L., Pezzetta F. Inhibition Of the renin"angiotensin system in patients with COPD and pulmonary hypertension" response. Chest. 2007; 131 (3): 938–939.
(check this in PDF content)
17
Zhang H., Li Y., Zeng Y. et al. Endothelin"1 downregulates angiotensin"converting enzyme"2 expression in human bronchial epithelial cells. Pharmacology. 2013; 91 (5–6): 297–304.
(check this in PDF content)
18
Martiniuc C., Braniste A., Braniste T. Angiotensin converting enzyme inhibitors and pulmonary hypertension. Rev. Med. Chir. Soc. Med. Nat. Iasi.2012; 116 (4): 1016–1020.
(check this in PDF content)
19
Petersen H., Sood A., Meek P.M. et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin"converting enzyme inhibitor use. Chest. 2014; 145 (4): 695–703.
(check this in PDF content)
20
Орлов В.А., Гиляревский С.Р., Урусбиева Д.М., Даурбе" кова Л.В. Влияние побочных эффектов ингибиторов ан" гиотензин"превращающего фермента на тактику лече" ния сердечно"сосудистых заболеваний. Российский кар# диологический журнал. 2005; 3: 79–91.
(check this in PDF content)
21
Евдокимова А.Г., Евдокимов В.В., Радзевич А.Э., Ольхин В.А. Место нитратов в лечении сердечно"сосудистых за" болеваний: научные доказательства и клиническая прак" тика. Справочник поликлинического врача. 2013; 2: 24–29.
(check this in PDF content)
22
Girard A., Jouneau S., Chabanne C. et al. Severe pulmonary hypertension associated with COPD: Hemodynamic impro" vement with specific therapy. Respiration. 2015; 90 (3): 220–228.
(check this in PDF content)
23
Chandy D., Aronow W.S., Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pul" monary disease. Integr. Blood Press. Control.2013; 6: 101–109.
(check this in PDF content)
24
Яхонтов Д.А., Балабанова Н.Ф. Возможности антагонис" тов кальция третьего поколения в лечении больных арте" риальной гипертензией в сочетании с хронической обструктивной болезнью легких. Рациональная фармако# терапия в кардиологии.2010; 6 (3): 339–344.
(check this in PDF content)
25
Sharif"Kashani B., Hamraghani A., Salamzadeh J. et al. The effect of amlodipine and sildenafil on the NT"ProBNP level of patients with COPD"induced pulmonary hypertension. Iran. J. Pharm. Res.2014; 13: 161–168.
(check this in PDF content)
26
Ватутин Н.Т., Шевелек А.Н., Дегтярева А.Э., Касем С.С. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериаль" ной гипертензии. Журнал национальной академии меди# цинских наук.2014; 20 (1): 43–52.
(check this in PDF content)
27
G?uszek J. Ischaemic heart disease and hypertension in patients with chronic obstructive pulmonary disease andob" structive sleep apnoea.Pneumonol. Alergol. Pol.2013; 81 (6): 567–574.
(check this in PDF content)
28
Bahammam A. Obstructive sleep apnea: from simple upper airway obstruction to systemic inflammation. Ann. Saudi. Med. 2011; 31: 1–3.
(check this in PDF content)
29
Lee R., McNicholas W.T. Obstructive sleep apnea in chronic obstructive pulmonary disease patients.Curr. Opin. Pulm. Med. 2011; 17: 79–83.
(check this in PDF content)
30
Curkendall S.M., DeLuise C., Jones J.K. Chronic obstructive pulmonary disease severity and cardiovascular outcomes.Eur. J. Epidemiol.2006; 16: 63–70.
(check this in PDF content)
31
Коррейа Л.Л., Лебедев Т.Ю., Ефремова О.А. и др. Проб" лема полиморбидности при сочетании хронической обструктивной болезни легких и некоторых сердечно" сосудистых заболеваний.Научные ведомости БелГУ. Се" рия: Медицина. Фармация. 2013; 4 (147): 12–17.
(check this in PDF content)
32
Sheng X., Murphy M.J., MacDonald T.M. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all"cause mortality in chronic obstructive pulmonary disease: a population"based cohort study. Clin. Ther. 2012; 34: 374–384.
(check this in PDF content)
33
Lawes C.M., Thornley S., Young R. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J.2012; 21: 35–40.
(check this in PDF content)
34
Cao C., Wu Y., Xu Z. et al. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: Ватутин Н.Т., Смирнова А.С.Коморбидность ХОБЛ и сердечно"сосудистой патологии: особенности лечения a systematic review and meta"analysis of observational rese" arch.Sci. Rep. 2015; 5: 16461.
(check this in PDF content)
35
Blamoun A.I., Batty G.N., DeBari V.A. et al. Statins may reduce episodes of exacerbation and the requirement for intu" bation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract.2008; 62: 1373–1378.
(check this in PDF content)
36
Huang C.C., Chan W.L., Chen Y.C. Statin use and hospital" ization in patients with chronic obstructive pulmonary dis" ease: a nationwide population"based cohort study in Taiwan. Clin. Ther. 2011; 33: 1365–1370.
(check this in PDF content)
37
Jiang X., Yuan L., Li P. et al. Effect of simvastatin on 5"HT and 5"HTT in a rat model of pulmonary artery hypertension. Cell. Physiol. Biochem. 2015; 37 (5): 1712–1724.
(check this in PDF content)
38
Курлянская Е.К., Атрощенко Е.С., Геворкян Т.Т., Дени" севич Т.Л. Аспирин в структуре антиагрегантной терапии сердечно"сосудистых заболеваний.Медицинские новос# ти.2007; 8: 46–48.
(check this in PDF content)
39
Sin D.D. The devastating power of platelets in COPD exacer" bations: can aspirin save lives in COPD? Thorax. 2014; 69 (7): 603–604.
(check this in PDF content)
40
Harrison M.T., Short P., Williamson P.A. et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014; 69 (7): 609–615.
(check this in PDF content)
41
Winning J., Reichel J., Eisenhut Y. et al. Anti"platelet drugs and outcome in severe infection: clinical impact and underly" ing mechanisms. Platelets. 2009; 20: 50–57.
(check this in PDF content)
42
Cooper"DeHoff R.M., Handberg E.M., Mancia G.Q. et al. INVEST revisited: review of findings from the International Verapamil SR"Trandolapril Study. Exp. Rev. Cardiovasc. Ther. 2009; 7 (11): 1329–1340.
(check this in PDF content)
43
Diaz A. Long"term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J.2005; 26: 967–974.
(check this in PDF content)
44
Salpeter S.R. Cardiovascular safety of beta(2)"adrenoceptor agonist use in patients with obstructive airway disease: a sys" tematic review. Drugs Aging.2004; 21 (6): 405–414.
(check this in PDF content)
45
Calverley P.M.A., Anderson J.A., Celli B. Salmeterol and flu" ticasone propionate and survival in chronic obstructive pul" monary disease. N. Engl. J. Med.2007; 356: 775–789.
(check this in PDF content)
46
Ferri C. Strategies for reducing the risk of cardiovascular dis" ease in patients with chronic obstructive pulmonary disease. High Blood Press Cardiovasc. Prev.2015; 22 (2): 103–111.
(check this in PDF content)
47
Провоторов В.М., Коточигова Т.В. Фармакотерапия хро" нической обструктивной болезни легких и хронической сердечной недостаточности. Молодой ученый.2011; 6 (2): 187–189.
(check this in PDF content)
48
Терехова Е.П., Терехов Д.В. Место ингибитора фосфо" диэстеразы"4 рофлумиласта в терапии хронической обструктивной болезни легких. Трудный пациент. 2014; 10 (12): 44–51.
(check this in PDF content)
49
Herych P.R., Iatsyshyn R.I. Treatment and prevention of combined cardio"respiratory pathology in exacerbation of chronic obstructive pulmonary disease (new approach). Lik. Sprava.2014; (7–8): 38–46 (in Ukrainian). Поступила 08.12.15
(check this in PDF content)